DEA Application for Bulk Manufacturer of Controlled Substances: Siegfried Grafton, Inc.

FR: Drug Enforcement Administration

Published March 19th, 2026

Detected March 19th, 2026

Summary

The Drug Enforcement Administration (DEA) has published a notice regarding an application from Siegfried Grafton, Inc. to be registered as a bulk manufacturer of various controlled substances, including Schedule I and II drugs. The application is open for public comment and objections until May 18, 2026.

View original document View source feed page

What changed

The Drug Enforcement Administration (DEA) has issued a notice concerning an application from Siegfried Grafton, Inc. for registration as a bulk manufacturer of controlled substances. The application covers a comprehensive list of Schedule I and II drugs, including lysergic acid diethylamide, marihuana, tetrahydrocannabinols, and various opioids and stimulants. The company intends to manufacture these substances for analytical reference standards or for sale to customers, with specific notes on synthetic manufacturing for marihuana and tetrahydrocannabinols.

Regulated entities, particularly existing bulk manufacturers of the affected controlled substances, have until May 18, 2026, to submit electronic comments or objections to the DEA. They may also file a written request for a hearing by the same date. Failure to act by this deadline may result in the approval of Siegfried Grafton, Inc.'s application without further opportunity for input.

What to do next

Review the application details for Siegfried Grafton, Inc.
Submit electronic comments or objections to the DEA by May 18, 2026, if applicable.
File a written request for a hearing by May 18, 2026, if applicable.

Source document (simplified)

Notice

Bulk Manufacturer of Controlled Substances Application: Siegfried Grafton, Inc.

A Notice by the Drug Enforcement Administration on 03/19/2026

This document has a comment period that ends in 60 days.
(05/18/2026) View Comment Instructions
PDF
Document Details
Document Dates

- Table of Contents

Public Comments
Regulations.gov Data

- Sharing

Print
Other Formats
Public Inspection Published Document: 2026-05358 (91 FR 13337) Document Headings ###### Department of Justice

Drug Enforcement Administration

[Docket No. DEA-1682]

AGENCY:

Drug Enforcement Administration, Justice.

ACTION:

Notice of application.

SUMMARY:

Siegfried Grafton, Inc. has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

DATES:

Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before May 18, 2026. Such persons may also file a written request for a hearing on the application on or before May 18, 2026.

ADDRESSES:

The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to https://www.regulations.gov and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on https://www.regulations.gov. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment.

SUPPLEMENTARY INFORMATION:

In accordance with 21 CFR 1301.33(a), this is notice that on February 25, 2026, Siegfried Grafton, Inc., 870 Badger Circle, Grafton, Wisconsin 53024-0000, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s):

| Controlled substance | Drug
code | Schedule |
| --- | --- | --- |
| Lysergic acid diethylamide | 7315 | I |
| Marihuana Extract | 7350 | I |
| Marihuana | 7360 | I |
| Tetrahydrocannabinols | 7370 | I |
| 4-Bromo-2,5-dimethoxy- phenethylamine | 7392 | I |
| 3,4-Methylenedioxy- amphetamine | 7400 | I |
| 3,4-Methylenedioxy- methamphetamine | 7405 | I |
| 5-Methoxy-N-N-dimethyltryptamine | 7431 | I |
| Dimethyltryptamine | 7435 | I |
| Psilocybin | 7437 | I |
| Psilocyn | 7438 | I |
| Lisdexamfetamine | 1205 | II |
| Methylphenidate | 1724 | II |
| Amobarbital | 2125 | II |
| Nabilone | 7379 | II |
| ANPP (4-Anilino-N-phenethyl-4-piperidine) | 8333 | II |
| Hydrocodone | 9193 | II |
| Opium extracts | 9610 | II |
| Opium, powdered | 9639 | II |
| Opium, granulated | 9640 | II |
| Opium poppy | 9650 | II |
| Noroxymorphone | 9668 | II |
| Remifentanil | 9739 | II |
| Fentanyl | 9801 | II |
The company plans to bulk manufacture the listed controlled substances for purpose of analytical reference standards or for sale to its customers. In reference to drug codes 7360 (Marihuana), and 7370 (Tetrahydrocannabinols), the company plans to bulk manufacture these drugs as synthetic. No other activities for these drug codes are authorized for this registration.